From: Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients
Patients with persistent DME
Month 3 (week 12)
(n/N, %)
Month 6 (week 24)
(n/N; %)
Aflibercept (Eylea®)
95/187 (50.80%)
60/190 (31.58%)
Ranibizumab (Lucentis®)
91/171 (53.22%)
73/176 (41.48%)
Bevacizumab (Avastin®)
129/177 (72.88%)
118/180 (65.56%)